Background: Beta-blockers are underprescribed for coronary artery disease (CAD) patients in Japan. Considering the vast amount of evidence showing their benefits in this group of patients, the aim of the present study was to investigate the use of β-blockers in a large cohort of CAD patients.
eta-blockers are underprescribed by Japanese physicians, possibly because of their deleterious effects on metabolic profiles, 1,2 and patients with bronchial insufficiency, 3 or physicians' high awareness of bradycardia and hypotension induced by the drugs. It has been reported that even for patients with myocardial ischemia, calcium antagonists are preferred over β-blockers for the treatment of angina, 4 maybe from fear of coronary spasm, the rate of which is reported to be higher in the Japanese population than in Westerners. 5 Although β-blockers were being used off-label for congestive heart failure (CHF) in clinical settings, it was only in 2002 that carvedilol was officially approved for the treatment of CHF in Japan. Today, carvedilol remains the only β-blocker approved for the treatment of CHF in Japan. On the other hand, there is ample evidence that β-blockers are beneficial in reducing cardiovascular risks in many conditions. 6-9
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We conducted a large observational study (the JCAD study) to investigate the background and treatment of Japanese patients with confirmed coronary artery disease (CAD), defined as ≥75% stenosis in at least 1 branch of the coronary arteries in accordance with the American Heart Association (AHA) classification. We concluded that β-blockers were less likely to be prescribed in Japan than in the West, 10 but considering the enormous evidence of the beneficial effects of β-blockers in patients with cardiovascular diseases, we felt that a more thorough investigation of β-blocker usage was necessary. It has also been reported that different β-blockers produce different outcomes in certain situations, 11 so in the present study we looked at how various classes of β-blockers are used and what effects they had on outcomes.
Methods

Patients
The protocol and major outcomes of this study have been published previously. 12, 13 Briefly, patients who underwent coronary angiography (CAG) at each participating institute and who were diagnosed as having ≥75% stenosis according to the AHA classification in at least 1 branch of the coronary arteries were registered. All CAGs were performed with Beta-Blocker Usage in JCAD Study written informed consent. Of the 15,628 patients who were initially registered in the study, 13,812 were followed up and included in the present analysis. Among these, 10,626 of the patients were male and 3,186 were female. Diagnoses at the time of registration included the following: acute myocardial infarction (2,955 patients), history of myocardial infarction (OMI: 3,913 patients), and unstable angina pectoris (UAP: 2,049). Patients were followed up for an average of 2.7 years. Figure 1 . The continuation rate of each class of drug was calculated as the rate of patients who took the medication from the time of discharge through to final follow-up date. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker; CCB, calcium-channel blocker; AT, antithrombotic. KOHRO T et al.
Data Registration and Gathering
All follow-up data were gathered electronically over the internet. At the time of registration, a diagnosis of CAD had been given by the attending physician. The brand names and dosages of all the drugs that the patients were taking were registered by the attending physicians. The definition of each risk factor was as follows: smoking, at least 1 incidence of smoking in the 2 years prior to registration; hyperlipidemia, serum total cholesterol ≥220 mg/dl and/or low-density-lipoprotein cholesterol ≥140 mg/dl and/or triglycerides ≥150 mg/dl; impaired fasting glycemia (IFG), defined as fasting blood glucose ≥110 mg/dl (diabetes mellitus was included in this study); hypertension, systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg; obesity, body 
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mass index ≥25; familial history, first-degree relative with CAD; and drinking, having a habit of alcohol consumption. These data were obtained from each patient by the attending physicians. Careful attention was paid to data security.
Investigations
The endpoints in this report are the composite of all-cause deaths and cardiocerebrovascular events, the latter comprising cardiac events, cerebral events and vascular events, and some of the components of the composite endpoint (ie, all-cause deaths, cardiac events and cerebral events). Cardiac events were defined as fatal and non-fatal myocardial infarction (MI), UAP, CHF, coronary bypass graft surgery, resuscitated cardiac arrest or cardiopulmonary arrest on arrival. Cerebral events were defined as cerebral hemorrhage, cerebral infarction or transient ischemic attack. Aortic dissection and rupture of aortic aneurysm were classified as vascular events. All events were assessed and registered by the attending physicians.
Ethical Considerations
The protocol used in this study was approved by the Central Institutional Review Board of the University of Tokyo. Written informed consent was given by all patients.
Statistical Analyses
For each class of drugs, the continuation rate was defined as the rate of patients who took the medication from the time of discharge through to follow-up date. Because the data for each patient, including prescriptions, were registered by the attending physicians every 6 months, we assumed that a drug was discontinued if a patient continued to be followed up, but the drug that the patient had been prescribed was not registered. The logistic model, which included both patient background characteristics (age, sex, hypertension, hyperlipidemia, IFG, obesity, smoking, drinking of alcohol, family history of CAD, CHF, left main trunk disease, and number of affected arteries) and drug classes (statins, fibrates, calciumchannel blockers (CCBs), angiotensin-converting enzyme inhibitors (ACEIs), angiotensin-receptor blocker (ARBs), α-1 blockers, antithrombotics (ATs), and nitrates) was used to generate a propensity score for each individual in the dataset. Propensity score matching was performed using a 5-digit, greedy 1:1 matching algorithm. 14 Kaplan-Meier curves were depicted with hazard ratios (HR) calculated by univariate Cox regression analysis to examine incidence over time. Data for patients who were lost to follow-up were censored at the time of last contact. Medication at the time of discharge was used for survival analysis, which was performed on the assumption that the medication did not change through the follow-up period (intention-to-treat principle). Statistical analysis was performed with SAS version 9.1 (SAS Institute Inc, Cary, NC, USA).
Results
Patients' Backgrounds
As shown in Table 1 , those patients who were given β-blockers had significantly higher rates of hypertension, hyperlipidemia, obesity, family history of ischemic diseases and had a higher number of diseased arteries. With regard to concomitantly prescribed drugs, those patients who were given β-blockers were also significantly more likely to be prescribed statins, fibrates, α-1 blockers, ACEIs, ARBs, and ATs, and were significantly less likely to be prescribed CCBs. Figure 1 shows the continuation rate of several classes of drugs that were prescribed for the patients in this cohort. Fibrates continued to be administered to 70.5% of the patients who were prescribed the medicine at the time of 
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discharge, while ARBs, CCBs, β-blockers, statins, and ATs continued to be administered to over 90% of the patients who were prescribed the drugs at the time of discharge.
Continuation Rate of β-Blockers When Classified According to Lipophilicity/Receptor Binding Specificity
Beta-blockers can be classified according to their solubility or ability to specifically bind to β-1 receptors. Table 2 shows the classification, number of patients taking the drug, and mean dosage of all the β-blockers that physicians prescribed in this study. Figure 2 shows the continuation rate for β-blockers of each class. The continuation rate of hydrophilic β-blockers (84.4%) was significantly lower than that of lipophilic β-blockers (89.3%, P<0.001). The continuation rate of non-selective β-blockers (79.1%) was significantly lower than that of β-1-selective β-blockers (87.2%, P=0.003) or α-β-selective β-blockers (87.7%, P=0.002).
Effect of β-Blockers on Endpoints
In order to investigate the effect of β-blockers, we performed a propensity score matching analysis. Those who were given β-blockers at discharge were matched with those who were not given β-blockers at discharge. As shown in Table 3 , all background characteristics and medication were well matched. Figure 3 shows the Kaplan-Meier plot for endpoint accumulation and HRs. There were no significant differences between those who were given β-blockers and those were not given β-blockers for any of the endpoints.
Differences in Effect of β-Blockers on Endpoints According to Lipophilicity
We sought to investigate if there were any differences in effectiveness between lipophilic and hydrophilic β-blockers on the endpoints. We performed propensity score matching between those who were given lipophilic β-blockers and those who were given hydrophilic β-blockers. As shown in Table 4 , all background characteristics and medication were well matched. Figure 4 shows the Kaplan-Meier plot for endpoint accumulation and HRs. For the composite endpoints, cardiac endpoints and cerebral endpoints, there were no significant differences between lipophilic and hydrophilic β-blockers for outcome. For all-cause mortality, lipophilic Figure 3 . Patients who were taking β-blockers were matched with those who were not taking β-blockers based on propensity scores calculated by logistic regression. Kaplan-Meier analysis was performed on the 2 groups with various endpoints. HR, hazard ratio; CI, confidence interval.
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β-blockers showed a significantly better outcome compared to hydrophilic β-blockers (HR 0.467, 95% confidence interval 0.247-0.880, P=0.019).
Discussion
In this study of a large cohort of Japanese patients with angiographically determined CAD, we showed that despite the low prescription rate of β-blockers among Japanese physicians, the continuation rate was relatively high and that lipophilic β-blockers may be a better choice than hydrophilic ones if mortality risks are considered. As mentioned earlier, Japanese physicians have been reluctant to adopt β-blockers as a treatment for hypertension. Although the guidelines for the management of hypertension published by the Japanese Society of Hypertension in 2009 include β-blockers as a first-line therapy for hypertension, 15 among Japanese physicians it is generally perceived that compared to CCBs, ACEIs and ARBs, β-blockers are more difficult to use because of their unfavorable effects on glucose metabolism 1,2 and pulmonary diseases. 16 Cardiologists are also highly aware of the bradycardia and hypotension induced by β-blockers. Previous reports have shown that even for patients with CAD, the prescription rate of β-blockers is significantly lower in Japan (≈30% 4,17 ) than in the West (≈85% 18 ).
That trend was also observed in this study, in which only 30.1% of CAD patients were prescribed β-blockers. Despite the fact that in this study we combined α-β-blockers and pure β-blockers under the same classification of β-blockers, unlike in our previous report, 10 the overall prescription rate was still lower than that reported in Western studies.
However, this study showed that the adherence rate of β-blockers was over 90%, suggesting that for those patients in whom β-blockers were indicated, the attending physician abided by the prescription and β-blockade therapy was well tolerated. We could not show any beneficial effect of β-blockers on such endpoints as cardiac events, all-cause mortality, cerebral events, or the composite of such events (Figure 3) , even when we matched the background and medication pattern of those who were given β-blockers and those who were not ( Table 3) . Before matching, patients who were prescribed β-blockers had a significantly higher rate of hypertension, hyperlipidemia, obesity, family history of CAD and a higher number of diseased arteries ( Table 1) . It is possible that other factors that were not measured in this study were unbalanced between the groups and affected the results so that beneficial effects were not observed for β-blockers. This problem in evaluating the efficacy of drugs in observational studies is known as "confounding by indication". 19 Beta-blockers can be classified according to such properties as lipophilicity, β-receptor-blockade specificity and intrinsic sympathomimetic activity, which, aside from the class effect of β-blockers, reportedly cause differences in various outcomes, 20 with several clinical studies supporting this claim. 7,8, 21 In the present study, lipophilic β-blockers reduced the risk of all-cause mortality significantly more than hydrophilic β-blockers, which is in contrast to a recent observational study that showed that the survival rate among 3 β-blockers, 2 of which were lipophilic and 1 of which was hydrophilic, did not differ after acute MI when adjusted for several factors. 22 However, the results of several randomized, controlled clinical trials using a hydrophilic β-blocker have failed to show any benefit in reducing cardiovascular or all-cause mortality against placebo in hypertensive patients. 21, 23 Although the findings in our study cannot be directly extrapolated to daily practice, careful consideration may be needed when selecting a medication.
Although β-blockers have recently been called into ques- 28 We could not show that β-blockers as a class confer beneficial effects in reducing cardiovascular, cerebrovascular or all-cause mortality endpoints nor the composite of such endpoints in this study, which may be attributed to "confounding by indication". Within the β-blocker drug class, it appears that lipophilic β-blockers may be superior to hydrophilic β-blockers in reducing all-cause mortality, although a randomized controlled study is needed to confirm that result.
In conclusion, this study showed that despite the low prescription rate of β-blockers for CAD patients among Japanese physicians, the continuation rate was relatively high, which suggests that they are well tolerated. We could not show a clear benefit of β-blockers for various outcomes, which might be attributed to "confounding by indication". Better outcomes with lipophilic β-blockers compared with hydrophilic β-blockers were observed for all-cause mortality, although further investigation is needed to confirm this finding.
Adherence to guidelines that are based on rigid scientific evidence is necessary for the improvement of care, and observational studies similar to the JCAD study are warranted in the future to monitor and improve cardiovascular care.
Study Limitations
This study was an observational study and not a randomized controlled study. Although survival analysis was performed with propensity score matching, it is possible that factors that were not measured in this study were skewed between groups and affected the results. One major factor could be chronic kidney disease. No data regarding renal function was obtained in this study because, unlike the way it is viewed today, it was not regarded as a strong component of cardiovascular risk at the time the study was planned. It should also be noted that while analysis was performed on the assumption that patients were continually taking the medicines, it is possible that the prescription at the time of discharge was changed later in the follow-up period, which is suggested in the results of the continuation rate of drugs we have shown. Patients who were taking lipophilic β-blockers were matched with those who were taking hydrophilic β-blockers based on propensity scores calculated by logistic regression. Kaplan-Meier analysis was performed on the 2 groups with various endpoints. HR, hazard ratio; CI, confidence interval.
